Capital Corp Merchant Banking Background

One of the biggest advances may turn out to be the development of “new science”, which targets the causes of the disease rather than the symptoms. This new field is expected to significantly reduce development times and decrease marketing costs. Unfortunately, at this time the benefits are not exceeding expenses, but are anticipated to provide substantial future growth potential for the industry.

MRE has struggled in recent years. This year also appears dim as they will lose many important products, allowing generic drugs to compete for these sales. The divesture of subsidiaries in 2002 provided new capital for R&D, but also cost them what could have been a valuable asset as a generic online in this declining economy. MRE’s shares underperformed those of its peers, which has worried investors and has the potential for driving down the stock even further.